Sakar Healthcare Latest Share Price (SAKAR)
TODAY IN ONE LINE
SAKAR fell 1.6% on light volume, lagging Nifty's 0.5% move, supported by recent strong earnings.
With a market cap of ₹1,972.68 Cr., it trades at a P/E of 56.29. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
Sakar Healthcare flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Earnings GrowthEPS (TTM) grew by a solid 87.2% YoY
- ●Quarterly OutperformanceLatest quarter Sales up 41.5% and Profit up 91.3%
- ●Healthy Operating MarginsOPM is structurally strong at 27.4%
- ●High Promoter HoldingPromoters hold 52.9% skin-in-the-game
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.17x
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Poor Capital ReturnsLow ROE of 10.0%
- ●Expensive ValuationTrading at a high P/E ratio of 59.1x
Latest Sakar Healthcare News
What changed recently?
Recent events, corporate actions, and announcements.
Sakar Healthcare Limited valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Sakar Healthcare Limited, framed against the sector median so the premium or discount is obvious at a glance.
Sakar Healthcare Limited trades at a P/E of 56.29× and P/B of 6.26×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
Sakar Healthcare Limited technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for Sakar Healthcare Limited — derived from the latest tape, not yesterday's close.
Sakar Healthcare Limited last traded at ₹884.85 with an intraday range of ₹872.3–₹920 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹884.85| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 1007.87 | +123.02 | +13.90% |
| R3 | 960.17 | +75.32 | +8.51% |
| R2 | 940.08 | +55.23 | +6.24% |
| R1 | 912.47 | +27.62 | +3.12% |
| PIVOT | 892.38 | 7.53 | 0.85% |
| CURRENT | 884.85 | — | — |
| S1 | 864.77 | -20.08 | -2.27% |
| S2 | 844.68 | -40.17 | -4.54% |
| S3 | 817.07 | -67.78 | -7.66% |
| S4 | 769.37 | -115.48 | -13.05% |
SAKAR is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹872.3–₹906.45
Trading Below opening range, showing Bearishness
Sakar Healthcare Limited financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for Sakar Healthcare Limited — consolidated or standalone — with margins, YoY growth and key ratios inline.
Sakar Healthcare Limited reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹1,972.68 Cr. and reported EPS of ₹13.68.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 178 | 252 ▲ 41.8% |
| Sales Growth YoY %Derived | 15.80% | 41.76% |
| Other Income | 1 | 2 ▲ 74.3% |
| Total Income | 179 | 254 ▲ 42.0% |
| 82 | 123 ▲ 49.9% | |
| Gross ProfitDerived | 95 | 128 ▲ 34.8% |
| Gross Margin %Derived | 53.68% | 51.03% |
| 46 | 60 ▲ 30.5% | |
| EBITDA (Operating Profit)Derived | 50 | 69 ▲ 38.7% |
| OPM %Derived | 27.98% | 27.37% |
| 29 | 31 ▲ 7.0% | |
| Profit Before Tax (PBT) | 22 | 40 ▲ 84.7% |
| 4 | 9 ▲ 130.3% | |
| Effective Tax %Derived | 18.70% | 23.32% |
| Total Profit for Period | 18 | 30 ▲ 74.2% |
| Net Profit (Owner's PAT)Derived | 18 | 30 ▲ 74.2% |
| Net Profit Margin %Derived | 9.86% | 12.11% |
| PAT Growth YoY %Derived | 49.96% | 74.18% |
| Earnings Per Share (EPS ₹) | 7.97 | 13.70 ▲ 71.9% |
| Diluted Shares Outstanding (Cr) | 2 | 2 ▲ 1.4% |
| Other Comprehensive Income (Net of Tax) | -0 | -0 ▲ 8.8% |
| Total Expenses (incl. D&A & Interest) | 157 | 214 ▲ 36.2% |
| Material Cost % of RevenueDerived | 53.76% | 52.71% |
| Employee Cost % of RevenueDerived | 17.82% | 15.38% |
| Other Cost % of RevenueDerived | 7.88% | 8.28% |
| Interest Coverage (x)Derived | 3.37x | 5.77x |
| Period | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|
| Revenue from Operations | 95 | 128 ▲ 35.3% | 133 ▲ 4.0% | 153 ▲ 15.0% | 178 ▲ 15.8% | 252 ▲ 41.8% | |
| Sales Growth YoY %Derived | — | 35.35% | 4.00% | 14.99% | 15.80% | 41.76% | |
| Other Income | 1 | 2 ▲ 84.7% | 5 ▲ 115.3% | 3 ▼ 32.0% | 1 ▼ 58.7% | 2 ▲ 74.3% | |
| Total Income | 96 | 130 ▲ 36.0% | 138 ▲ 5.9% | 157 ▲ 13.4% | 179 ▲ 14.3% | 254 ▲ 42.0% | |
51 | 74 ▲ 45.6% | 74 ▼ 1.2% | 84 ▲ 13.8% | 82 ▼ 1.7% | 123 ▲ 49.9% | ||
| Gross ProfitDerived | 44 | 54 ▲ 23.3% | 60 ▲ 11.2% | 70 ▲ 16.5% | 95 ▲ 36.8% | 128 ▲ 34.8% | |
| Gross Margin %Derived | 46.05% | 41.96% | 44.85% | 45.43% | 53.68% | 51.03% | |
21 | 24 ▲ 16.4% | 27 ▲ 9.0% | 31 ▲ 17.4% | 46 ▲ 45.8% | 60 ▲ 30.5% | ||
| EBITDA (Operating Profit)Derived | 23 | 29 ▲ 29.8% | 33 ▲ 13.0% | 38 ▲ 15.8% | 50 ▲ 29.5% | 69 ▲ 38.7% | |
| OPM %Derived | 23.85% | 22.87% | 24.85% | 25.02% | 27.98% | 27.37% | |
11 | 13 ▲ 19.2% | 21 ▲ 66.6% | 26 ▲ 22.5% | 29 ▲ 14.5% | 31 ▲ 7.0% | ||
| Profit Before Tax (PBT) | 13 | 19 ▲ 43.1% | 17 ▼ 10.9% | 16 ▼ 5.8% | 22 ▲ 35.4% | 40 ▲ 84.7% | |
3 | 4 ▲ 47.1% | 4 ▲ 9.7% | 4 ▲ 2.7% | 4 ▼ 4.8% | 9 ▲ 130.3% | ||
| Effective Tax %Derived | 19.27% | 19.82% | 24.40% | 26.60% | 18.70% | 23.32% | |
| Total Profit for Period | 11 | 15 ▲ 42.1% | 13 ▼ 16.0% | 12 ▼ 8.5% | 18 ▲ 50.0% | 30 ▲ 74.2% | |
| Net Profit (Owner's PAT)Derived | 11 | 15 ▲ 42.1% | 13 ▼ 16.0% | 12 ▼ 8.5% | 18 ▲ 50.0% | 30 ▲ 74.2% | |
| Net Profit Margin %Derived | 11.28% | 11.84% | 9.57% | 7.61% | 9.86% | 12.11% | |
| PAT Growth YoY %Derived | — | 42.10% | -15.95% | -8.53% | 49.96% | 74.18% | |
| Earnings Per Share (EPS ₹) | 6.84 | 8.73 ▲ 27.6% | 6.70 ▼ 23.3% | 5.37 ▼ 19.9% | 7.97 ▲ 48.4% | 13.70 ▲ 71.9% | |
| Diluted Shares Outstanding (Cr) | 2 | 2 ▲ 9.6% | 2 ▲ 11.2% | 2 ▲ 14.2% | 2 ▲ 0.9% | 2 ▲ 1.4% | |
| Other Comprehensive Income (Net of Tax) | 0 | -0 ▼ 602.8% | -0 ▲ 8.7% | -0 ▲ 49.8% | -0 ▼ 9.5% | -0 ▲ 8.8% | |
| Total Expenses (incl. D&A & Interest) | 83 | 111 ▲ 34.8% | 121 ▲ 8.7% | 141 ▲ 16.1% | 157 ▲ 11.9% | 214 ▲ 36.2% | |
| Material Cost % of RevenueDerived | 54.91% | 57.32% | 55.42% | 55.46% | 53.76% | 52.71% | |
| Employee Cost % of RevenueDerived | 14.00% | 11.87% | 12.57% | 12.90% | 17.82% | 15.38% | |
| Other Cost % of RevenueDerived | 8.20% | 7.22% | 7.43% | 7.52% | 7.88% | 8.28% | |
| Interest Coverage (x)Derived | 5.86x | 6.79x | 3.05x | 2.68x | 3.37x | 5.77x |
Sakar Healthcare segment analysis : revenue and profit mix.
Disclosed business segments at Sakar Healthcare with their share of revenue and profit, switchable between consolidated and standalone reporting.
Sakar Healthcare discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for Sakar Healthcare Limited.
Our AI distills the core fundamental drivers supporting Sakar Healthcare Limited, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
Sakar Healthcare Limited's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Robust quarterly profit growth of 91.30% YoY demonstrates strong operational execution
Quarterly sales up 41.50% YoY indicates robust demand across therapeutic portfolio
Operating margin of 18.00% supports efficient cost management and pricing discipline
Low debt-to-equity ratio of 0.0017 ensures financial flexibility and borrowing capacity
Promoter holding of 52.86% signals strong long-term commitment and alignment
Key Risks.
High P/E of 59.12x signals premium valuation relative to peer median 23.3x
ROE of 9.99% and ROCE of 12.70% lag peer medians, indicating modest capital efficiency
Zero dividend yield limits income appeal and shareholder return mechanisms
Latest quarterly EPS grew 91.40% YoY but TTM EPS grew 87.20% YoY, showing volatility
Net debt of ₹848.66 Cr with minimal cash of ₹2.08 Cr raises liquidity sustainability concerns
Flip Conditions.
Valuation risk. a P/E above 73 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 8% would indicate weaker capital compounding.
Sakar Healthcare Limited peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Sakar Healthcare Limited is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
Sakar Healthcare Limited chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Sakar Healthcare Limited — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
Sakar Healthcare Limited delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Sakar Healthcare Limited over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Sakar Healthcare Limited stood at 46.4% of traded volume, against a 20-day average of 48.6%.
Sakar Healthcare announcements: results, concalls, ratings, M&A.
Filings Sakar Healthcare sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Sakar Healthcare files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 84 documents below.
Analysts/Institutional Investor Meet/Con. Call Updates
Sakar Healthcare Limited has informed the Exchange about Transcript of Con-Call.
Copy of Newspaper Publication
Sakar Healthcare Limited has informed the Exchange about Copy of Newspaper Publication
Analysts/Institutional Investor Meet/Con. Call Updates
Sakar Healthcare Limited has informed the Exchange about Link of Recording
Investor Presentation
Sakar Healthcare Limited has informed the Exchange about Investor Presentation
Analysts/Institutional Investor Meet/Con. Call Updates
Sakar Healthcare Limited has informed the Exchange about Schedule of meet/Conference Call.
Investor decks & rating reports.
Sakar Healthcare dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Sakar Healthcare has declared, sequenced by announce and record date.
Sakar Healthcare corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
Sakar Healthcare insider trading: promoter and management activity.
Promoter, director and designated-employee transactions in Sakar Healthcare as reported to SEBI — buying and selling signals from the people who know the business best.
Sakar Healthcare insider activity below tracks 2 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| Aarsh S. Shah | Insider | 27 Dec 2024 | buy | +1.00 L | ₹2.88 Cr. | ₹288.00 |
| Sanjay S. Shah | Insider | 27 Dec 2024 | buy | +1.00 L | ₹2.88 Cr. | ₹288.00 |
About Sakar Healthcare Limited: business, sector, key facts.
What Sakar Healthcare Limited does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Sakar Healthcare Limited operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: SAKAR.
Sakar Healthcare Limited is an Indian pharmaceutical company engaged in the research, development, manufacturing, and marketing of a diverse range of pharmaceutical products. Their operations encompass the entire production process, from initial research and development to final product marketing and distribution. The company's commitment to a wide spectrum of therapeutic areas allows them to cater to a broad patient base and market demand.
The company's product portfolio is extensive and includes various dosage forms to accommodate diverse patient needs and treatment preferences. These forms include liquid orals, tablets, capsules, dry powder syrups, dry powder injections, liquid injectables (SVP) in ampoules and vials, lyophilized injections, and oral solid dosages. This breadth of dosage forms allows for flexibility in administration and potentially improved patient compliance.
Sakar Healthcare's product offerings span a considerable number of therapeutic areas, indicating a wide range of medical conditions addressed by their formulations. These areas include antacids, antimalarials, anticoagulants, laxatives, anthelmintics, bronchodilators, anesthetics, antidepressants, sedatives, adrenergics, anti-infectives, diuretics, oxytocics, analgesics, antiemetics, antipsychotics, antifungals, PPIs, anticonvulsants, anti-inflammatories, antihistamines, and multivitamins. This diversified portfolio demonstrates a commitment to serving a wide range of patient needs.
Beyond the domestic Indian market, Sakar Healthcare actively participates in international trade, exporting its products to several key regions globally. These export destinations encompass Southeast Asia, other parts of Asia, various African countries (both Anglophone and Francophone), the Middle East and North Africa (MENA) region, and even the United States. This international reach significantly expands the company's market presence and potential for growth.
Established in 2004 and headquartered in Ahmedabad, India, Sakar Healthcare Limited has a history of providing pharmaceutical solutions. Their integrated approach, encompassing research, development, manufacturing, and marketing, positions them as a significant player within the Indian pharmaceutical industry and beyond, through its international exports. The company's success rests on its broad product portfolio, diverse therapeutic coverage, and global market reach.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- 3B Blackbio DX (3BBLACKBIO) Share PricePeer
- Abbott India (ABBOTINDIA) Share PricePeer
- Acutaas Chemicals (ACUTAAS) Share PricePeer
- Anlon Healthcare (AHCL) Share PricePeer
- Amanta Healthcare (AMANTA) Share PricePeer
- Other overvalued NSE stocksScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about Sakar Healthcare Limited (SAKAR).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Sakar Healthcare Limited (SAKAR)?
The current share price of Sakar Healthcare Limited (SAKAR) is ₹884.85. Today, the stock has declined by ₹14.65 (1.63%), trading in a range of ₹872.30 to ₹920.00. The stock opened at ₹900.00 with a trading volume of 77,175 shares.
02Is Sakar Healthcare Limited stock a good investment for long-term?
Sakar Healthcare Limited can be considered for long-term investment based on several factors. The company has a market capitalization of ₹1,972.68 Cr., P/E ratio of 56.29, ROE of 9.99%, and ROCE of 12.7%. The dividend yield stands at 0%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Sakar Healthcare Limited stock?
The 52-week high price of Sakar Healthcare Limited (SAKAR) is ₹980.00, while the 52-week low is ₹345.50. Currently trading at ₹884.85, the stock is 156.11% above its 52-week low and 9.71% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Sakar Healthcare Limited stock at the current price?
Whether to buy Sakar Healthcare Limited stock at ₹884.85 depends on multiple factors. The stock is currently trading with a P/E ratio of 56.29 and P/B ratio of 6.26. Today's performance shows a loss of 1.63%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Sakar Healthcare Limited and when is the next dividend?
Sakar Healthcare Limited offers a dividend yield of 0%, which means for every ₹100 invested at the current price of ₹884.85, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Sakar Healthcare Limited?
Sakar Healthcare Limited's key financial metrics include: P/E Ratio: 56.29, P/B Ratio: 6.26, ROE: 9.99%, ROCE: 12.7%, Dividend Yield: 0%, EPS: ₹13.68, Book Value: ₹145.98, and Debt-to-Equity: 0.17. The company's market cap stands at ₹1,972.68 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Sakar Healthcare Limited stock performing today in the market?
Sakar Healthcare Limited stock opened at ₹900.00 and is currently trading at ₹884.85, showing a decline of ₹14.65 (1.63%). The intraday high is ₹920.00 and low is ₹872.30. The trading volume stands at 77,175 shares, indicating moderate market participation today.
08What is the P/E ratio of Sakar Healthcare Limited and what does it indicate?
Sakar Healthcare Limited has a Price-to-Earnings (P/E) ratio of 56.29, which means investors are willing to pay 56.29 for every ₹1 of earnings. With an EPS of ₹13.68, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Sakar Healthcare Limited (SAKAR) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.